Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 60, Issue 10, 2009, Pages 2870-2879

  Charles Schoeman, Christina ^a,b   Watanabe, Junji ^a,b   Lee, Yuen Yin ^a,b   Furst, Daniel E ^a,b   Amjadi, Sogol ^a,b   Elashoff, David ^a,b   Park, Grace ^a,b   McMahon, Maureen ^b   Paulus, Harold E ^b   Fogelman, Alan M ^b   Reddy, Srinivasa T ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME; HAPTOGLOBIN; HEMOGLOBIN; HEMOPEXIN; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CELL FREE SYSTEM; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RACE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; APOLIPOPROTEIN A-I; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HAPTOGLOBINS; HEMOGLOBINS; HEMOPEXIN; HUMANS; LIPOPROTEINS, HDL; MALE; METHOTREXATE; MIDDLE AGED; PEROXIDASE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; SEVERITY OF ILLNESS INDEX;

EID: 70349780621     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24802     Document Type: Article

References (45)

1. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-2963
2. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol 2002;29:906-912
3. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-3587 (Pubitemid 350100691)
4. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1: 16-19
5. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996;37: 2473-2491 (Pubitemid 27051496)
6. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-1508 (Pubitemid 30743599)
7. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-1494 (Pubitemid 30743598)
8. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio [published erratum appears in J Clin Invest 1997;99:3043]. J Clin Invest 1997;99: 2005-2019
9. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774-782
10. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-154
11. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-2756 (Pubitemid 37498976)
12. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-1840 (Pubitemid 36828677)
13. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402-411 (Pubitemid 40220344)
14. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-732 (Pubitemid 40365093)
15. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54: 2541-2549 (Pubitemid 44205015)
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145
19. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-1317 (Pubitemid 32744255)
20. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007;34: 1459-1464 (Pubitemid 47067979)
21. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, Ge H, et al. Differential association of hemoglobin with pro-inflammatory high density lipoproteins in atherogenic/hyperlipidemic mice: a novel biomarker of atherosclerosis. J Biol Chem 2007;282:23698-23707 (Pubitemid 47311940)
22. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-488 (Pubitemid 32323377)
23. Navab M, Van Lenten BJ, Reddy ST, Fogelman AM. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation 2001;104:2386-2387 (Pubitemid 33108367)
24. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci U S A 1991;88:6457-6461 (Pubitemid 21914965)
25. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-1536
26. Koenig W, Khuseyinova N, Baumert J, Thorand B, Loewel H, Chambless L, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006;26:2745-2751
27. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005;112:25-31. (Pubitemid 40962565)
28. Del Rincon I, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52:3413-3423 (Pubitemid 41612207)
29. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48: 1530-1542 (Pubitemid 36682360)
30. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al. Anti-inflammatory therapy with tumour necrosis factor α inhibitors improves high-density lipid cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2008. E-pub ahead of print.
31. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66: 880-885 (Pubitemid 46999787)
32. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-1218 (Pubitemid 40995372)
33. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177 (Pubitemid 34304256)
34. Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009;68: 1271-1276
35. Wick G, Huber LA, Offner F, Winter U, Bock G, Schauenstein K, et al. Immunodeficiency in old age. Curr Probl Dermatol 1989;18: 120-130
36. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2:504-511 (Pubitemid 44353291)
37. Watson KE, Hama S, Fonarow GC, Ansell BJ, Navab M, Fogelman AM. Metabolic syndrome patients have higher plasma lipid hydroperoxides and more pro-inflammatory HDL than dyslipidemic control subjects, even with comparable levels of HDL, HS-CRP, and paraoxonase activity. Circulation 2004;110:III-53.
38. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000;28: 1717-1725
39. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003;91:12-6A.
40. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007;99:1364-1368 (Pubitemid 46686633)
41. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Karakukcu C, et al. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct 2006;24: 307-311 (Pubitemid 44065233)
42. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756 (Pubitemid 46348533)
43. Spagnuolo MS, Cigliano L, D'Andrea LD, Pedone C, Abrescia P. Assignment of the binding site for haptoglobin on apolipoprotein A-I. J Biol Chem 2005;280:1193-1198
44. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 2008;49:1344-1352
45. Charles-Schoeman C, Banquerigo ML, Hama S, Navab M, Park GS, Van Lenten BJ, et al. Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin Immunol 2008;127:234-244